CYP2D6 P34S polymorphism and outcomes of escitalopram treatment in Koreans with major depression

Psychiatry Investigation

Volumn 10, Issue 3, 2013, Pages 286-293

  Han, Kyu Man ^a,b   Chang, Hun Soo ^b   Choi, In Kwang ^a,b   Ham, Byung Joo ^a,b   Lee, Min Soo ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

CYP2D6 polymorphism; Escitalopram; Major depressive disorder; Treatment response

Indexed keywords

CYTOCHROME P450; ESCITALOPRAM;

ADULT; ALLELE; ARTICLE; AUTONOMIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA SEQUENCE; DRUG EFFICACY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; GENE FREQUENCY; GENETIC POLYMORPHISM; HAMILTON SCALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; POLYMERASE CHAIN REACTION; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT CHANGE;

EID: 84885725443     PISSN: 17383684     EISSN: 19763026     Source Type: Journal    
DOI: 10.4306/pi.2013.10.3.286     Document Type: Article

References (48)

1. Duffy A, Grof P, Robertson C, Alda M. The implications of genetics studies of major mood disorders for clinical practice. J Clin Psychiatry 2000;61:630-637.
2. Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci 2008;10:409-418.
3. Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-557.
4. Hamdani N, Gorwood P. Role of genetics in psychiatric treatment. Presse Med 2008;37:902-911.
5. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997; 60:265-271.
6. Baldwin DS, Reines EH, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007;41: 1583-1592.
7. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46:281-290.
8. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, et al. Identification of cytochrome P450 isoforms involved in citalopram Ndemethylation by human liver microsomes. J Pharmacol Exp Ther 1997; 280:927-933.
9. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001;29:1102-1109.
10. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit 2003;25:183-191.
11. Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther 2007;82:606-609.
12. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
13. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem 2000;46:18-23.
14. Lee MS. Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants. Drugs Today (Barc) 2007;43:569-581.
15. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, et al. Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010;71:1482-1487.
16. Mulder H, Wilmink FW, Beumer TL, Tamminga WJ, Jedema JN, Egberts AC. The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study. J Clin Psychopharmacol 2005;25:188-191.
17. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75:386-393.
18. D'Empaire I, Guico-Pabia CJ, Preskorn SH. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant? J Psychiatr Pract 2011;17:330-339.
19. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010;11:537-546.
20. Commitee N. The Human Cytochrome P450 (CYP) Allele. Available at: http://www.cypalleles.ki.se/cyp2d6.htm. Accessed March 14, 2013.
21. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001;250:186-200.
22. Nishida Y, Fukuda T, Yamamoto I, Azuma J. CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 2000;10:567-570.
23. Ji L, Pan S, Marti-Jaun J, Hanseler E, Rentsch K, Hersberger M. Singlestep assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel*14B allele in mainland Chinese. Clin Chem 2002;48:983-988.
24. Lee SY, Sohn KM, Ryu JY, Yoon YR, Shin JG, Kim JW. Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 2006; 28:382-387.
25. Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos 2008;36:2460-2467.
26. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-459.
27. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48:689-723.
28. Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992;14:49-58.
29. Jeon SO, Lee HY, Ham BJ, Kang RH, Jeong YJ, Lee MS. CYP2D6 P34S polymorphism and mirtazapine responses in Koreans with major de pression. Mol Cell Toxicol 2009;5:346-353.
30. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-855.
31. Kim JH, Choi SW, Joe SH, Ha TH, Yoo HJ, Choi JE, et al. Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder. Nord J Psychiatry 2008;62:496-502.
32. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-122.
33. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-192.
34. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009;29:39-43.
35. Ueda M, Hirokane G, Morita S, Okawa M, Watanabe T, Akiyama K, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:486-491.
36. LLerena A, Dorado P, Berecz R, Gonzalez AP, Penas-LLedo EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol 2004;59:869-873.
37. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H. CYP2D6* 10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003;58:659-661.
38. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009;48:761-804.
39. Bijl MJ, Luijendijk HJ, van den Berg JF, Visser LE, van Schaik RH, Hofman A, et al. Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. Pharmacogenomics 2009;10:541-547.
40. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003;167:443-448.
41. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160:1830-1835.
42. Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009;24:250-256.
43. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000;20:246-251.
44. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006;31:493-502.
45. Zourkova A, Ceskova E, Hadasova E, Ravcukova B. Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. J Sex Marital Ther 2007;33:343-355.
46. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004;59:803-807.
47. Breil F, Verstuyft C, Orostegui L, Buhl C, Alvarez JC, Chouinard G, et al. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. Int J Neuropsychopharmacol 2008; 11:727-728.
48. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60:329-336.